Trends in Receipt and Timing of Multimodality Therapy in Early-Stage Pancreatic Cancer
| dc.contributor.advisor | Kuo, Yong-Fang | |
| dc.contributor.committeeMember | Mehta, Hemalkumar | |
| dc.contributor.committeeMember | Brown, Kimberly | |
| dc.contributor.committeeMember | Riall, Taylor S | |
| dc.creator | Dimou, Francesca | |
| dc.creator.orcid | 0000-0002-3227-9371 | |
| dc.date.accessioned | 2016-05-05T21:26:18Z | |
| dc.date.available | 2016-05-05T21:26:18Z | |
| dc.date.created | 2015-12 | |
| dc.date.submitted | December 2015 | |
| dc.date.updated | 2016-05-05T21:26:18Z | |
| dc.description.abstract | Introduction Pancreatic cancer is considered a systemic disease at presentation. Therefore, multimodality therapy with surgical resection and chemotherapy is the standard of care for locoregional disease. We described treatment patterns and time trends with regard to age and treatment center in the receipt of multimodality therapy. Methods We used the National Cancer Data Base to identify patients ≥18 years old with stage I and II pancreatic adenocarcinoma. Treatment was defined as no treatment, resection only, chemotherapy only, or multimodality therapy, which consisted of both chemotherapy (neoadjuvant or adjuvant) and resection. Trends in the receipt and type of treatment were compared. Results Of 39,441 patients, 22.8 % of patients received no treatment, 18.5 % received chemotherapy only, 23.0 % underwent surgical resection alone, and 35.8 % of patients received multimodality therapy. Receipt of multimodality therapy increased from 31.3 % in 2004 to 37.9 % in 2011 (p < 0.0001). Patients >55 years were less likely to receive multimodality therapy (56–64 years: OR 0.83, 95 % CI 0.78–0.89; 65–75: OR 0.60, 95 % CI 0.55–0.65; ≥76: OR 0.17, 95 % CI 0.16–0.19 compared to patients 18–55). Compared to community hospitals, patients treated at an NCI-designated center were more likely to receive multimodality therapy (OR 1.62, 95 % CI 1.46–1.81) and, if they received multimodality therapy, delivery of chemotherapy in the neoadjuvant compared to adjuvant setting (OR 2.82, 95 % CI 2.00–3.98). Conclusion Despite increased use of multimodality therapy, it remains underutilized in all patients and especially in older patients. Receipt of multimodality therapy and neoadjuvant therapy is highly dependent on treatment at NCI-designated cancer centers. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.uri | http://hdl.handle.net/2152.3/654 | |
| dc.subject | Pancreatic cancer | |
| dc.subject | Multimodality therapy | |
| dc.title | Trends in Receipt and Timing of Multimodality Therapy in Early-Stage Pancreatic Cancer | |
| dc.type | Thesis | |
| dc.type.material | text | |
| thesis.degree.department | Clinical Science | |
| thesis.degree.grantor | The University of Texas Medical Branch at Galveston | |
| thesis.degree.level | Masters | |
| thesis.degree.name | Clinical Science (Masters) |